Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating ALE.P03 monotherapy in adults with selected advanced or metastatic Claudin-1 positive CLDN1 solid tumors, including colorectal cancer, intrahepatic cholangiocarcinoma, squamous non-small cell lung cancer, urothelial carcinoma, and cervical squamous cell carcinoma. The study includes Phase I dose escalation to determine the maximum tolerated dose and recommended dose for expansion, followed by Phase II to assess the recommended Phase II dose. The purpose is to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ALE.P03. Participants will receive ALE.P03 through intravenous infusion. In Phase I dose escalation, the dose is gradually increased until the maximum tolerated dose or a safe recommended dose is identified. In Phase I dose expansion, patients receive the safe recommended dose to confirm the recommended Phase II dose. In Phase II, participants receive ALE.P03 at the recommended Phase II dose or according to the dosing schedule after the expansion phase. Throughout the study, patients will undergo assessments including monitoring for dose limiting toxicities, adverse events, overall and duration of response, disease control rate, and survival outcomes up to four years. Blood samples will be collected for detailed pharmacokinetic and antibody analyses from treatment initiation until the end of treatment. Safety follow-up occurs up to 30 days after the last dose, with long-term monitoring extending up to four years. The study evaluates both clinical outcomes and biological measures to understand the effects of ALE.P03.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to the chemotherapy drug docetaxel in patients with non-small cell lung cancer NSCLC who have specific RAS gene mutations and have already received treatment. This global, randomized, open-label Phase 3 study aims to find out if daraxonrasib can improve how long patients live without their cancer worsening or overall survival compared to standard chemotherapy. Participants are randomly assigned to one of two groups one group receives daraxonrasib as oral tablets, and the other group receives docetaxel through intravenous infusion. The study follows patients over several years to compare the outcomes of these treatments. Patients receive treatment according to their assigned group and are monitored regularly throughout the study period. During the study, participants will have assessments including scans to measure tumor size, tests to check organ function, and questionnaires about quality of life. Researchers will evaluate progression-free survival and overall survival as main outcomes, along with the safety and tolerability of the treatments. The study lasts up to approximately four years, with ongoing monitoring of patients health and treatment responses.